2096 (2096) News
Follow 2096 (2096) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
M
Simcere gets NMPA approval to market Yingmule in China
Simcere Pharmaceutical Group Ltd says China’s NMPA has approved marketing of Yingmule in China.
GEOPOLITICS | Sep 03, 2026, 03:52 PM UTC
M
Roche to pay Simcere $75 million upfront for blood cancer drug rights
Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, Simcere said Tuesday.
EQUITY | Sep 01, 2026, 11:02 AM UTC
M
Simcere Pharmaceutical signs exclusive global licensing deal for SIM0660
Simcere Pharmaceutical Group entered an exclusive global licensing agreement with Roche for SIM0660, according to TradingView News.
EQUITY | Sep 01, 2026, 10:26 AM UTC